SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?


To: Paul Senior who wrote (18946)3/22/2004 10:51:37 PM
From: Spekulatius  Respond to of 78704
 
re ACRFY and HUWHY -
I looked at the last earnings report from ACRFY and the numbers looked quite dull to me: earnings 50% down,rooom rates down etc. Also the valuation does not look all that compelling. I never liked the capital intense hotel business with its' low ROE too much.

HUWHY - intriguing company imo ,but a dangerous investment at this point. Last earnings didn't sound good due to staggering 3G losses. The company is realizing gains on its investments, so the real situation is probably worse that the operating numbers presented by the company. The other business (harbors, Oil, trading) seem to be doing well, so i guess they will be able to dig themselves out of this hole but the NT outlook is not that great. I'll pass for now but keep on watching.



To: Paul Senior who wrote (18946)3/22/2004 11:04:55 PM
From: Spekulatius  Read Replies (4) | Respond to of 78704
 
Anybody follows drug stocks? I like ABT and PFE at current prices. Looks like the typical pre-election bear market for drug stocks is in place. If history is any guide this represents a buying opportunity. I posted on ABT already, as it is my current favorite. I believe that Humira is a blockbuster in the making and diagnostic division, which has resolved the non-compliance issues, is poised for a strong comeback.
forbes.com